Review
Open access
More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts
O. Langford
R. Raman
P. Aisen
R. Sperling
K. Johnson
D. Molina-Henry
P. Sachdev
D. Li
G. Jimenez-Maggiora
S. Johnson
J. Braunstein
C. Birkenbihl
M. Cuppels
R. Buckley
R. Rissman
M. Donohue
Medicine
Abstract
Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.